1 |
Greenwald AS, Boden SD, Goldberg VM, et al. The Committee on biological, bone-graft substitutes: facts, fictions, and applications [J]. J Bone Joint Surg Am, 2001, 2: 98-103.
|
2 |
Campana V, Milano G, Pagano E, et al. Bone substitutes in orthopaedic surgery: from basic science to clinical practice [J]. J Mater Sci Mater Med, 2014, 25(10): 2445-2461.
|
3 |
Fillingham Y, Jacobs J. Bone grafts and their substitutes [J]. Bone Joint J, 2016, 98-B(1 Suppl A): 6-9.
|
4 |
Abjornson C, Brecevich A, Callanan T, et al. ISASS recommendations and coverage criteria for bone graft substitutes used in spinal surgery [J]. Int J Spine Surg, 2018, 12(6): 757-771.
|
5 |
Vaggelas A, Seimetz D. Expediting drug development: FDA's new regenerative medicine advanced therapy designation [J]. Ther Innov Regul Sci, 2019, 53(3): 364-373.
|
6 |
Gillman CE, Jayasuriya AC. FDA-approved bone grafts and bone graft substitute devices in bone regeneration [J]. Mater Sci Eng C Mater Biol Appl, 2021, 130: 112466.
|
7 |
Schindeler A, McDonald MM, Bokko P, et al. Bone remodeling during fracture repair: The cellular picture [J]. Semin Cell Dev Biol, 2008, 19(5): 459-466.
|
8 |
Solheim E. Growth factors in bone [J]. Int Orthop, 1998, 22(6): 410-416.
|
9 |
Steinbrech DS, Mehrara BJ, Saadeh PB, et al. Hypoxia increases insulinlike growth factor gene expression in rat osteoblasts [J]. Ann Plast Surg, 2000, 44(5): 529-534; discussion 534-5.
|
10 |
El Bialy I, Jiskoot W, Reza Nejadnik M. Formulation, delivery and stability of bone morphogenetic proteins for effective bone regeneration [J]. Pharm Res, 2017, 34(6): 1152-1170.
|
11 |
Baldwin P, Li DJ, Auston DA, et al. Autograft, allograft, and bone graft substitutes: clinical evidence and indications for use in the setting of orthopaedic trauma surgery [J]. J Orthop Trauma, 2019, 33(4): 203-213.
|
12 |
Kang Q, Sun MH, Cheng H, et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery [J]. Gene Ther, 2004, 11(17): 1312-1320.
|
13 |
Gaihre B, Unagolla JM, Liu JY, et al. Thermoresponsive injectable Microparticle-Gel composites with recombinant BMP-9 and VEGF enhance bone formation in rats [J]. ACS Biomater Sci Eng, 2019, 5(9): 4587-4600.
|
14 |
Beederman M, Lamplot JD, Nan GX, et al. BMP signaling in mesenchymal stem cell differentiation and bone formation [J]. J Biomed Sci Eng, 2013, 6(8A): 32-52.
|
15 |
Charoenlarp P, Rajendran AK, Iseki S. Role of fibroblast growth factors in bone regeneration [J]. Inflamm Regen, 2017, 37: 10.
|
16 |
Ogilvie CM, Lu CY, Marcucio R, et al. Vascular endothelial growth factor improves bone repair in a murine nonunion model [J]. Iowa Orthop J, 2012, 32: 90-94.
|
17 |
Sun H, Lu PP, Zhou PH, et al. Recombinant human platelet-derived growth factor-BB versus autologous bone graft in foot and ankle fusion: A systematic review and meta-analysis [J]. Foot Ankle Surg, 2017, 23(1): 32-39.
|
18 |
Zhang ML, Yu WW, Niibe K, et al. The effects of Platelet-Derived growth Factor-BB on bone marrow stromal Cell-Mediated vascularized bone regeneration [J]. Stem Cells Int, 2018, 2018: 3272098.
|
19 |
James AW, LaChaud G, Shen J, et al. A review of the clinical side effects of bone morphogenetic protein-2 [J]. Tissue Eng Part B Rev, 2016, 22(4): 284-297.
|
20 |
Boden SD, Kang J, Sandhu H, et al. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies [J]. Spine (Phila Pa 1976), 2002, 27(23): 2662-2673.
|
21 |
Glassman SD, Dimar JR3, Burkus K, et al. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers [J]. Spine (Phila Pa 1976), 2007, 32(15): 1693-1698.
|
22 |
Ozkaynak E, Rueger DC, Drier EA, et al. OP-1 cDNA encodes an osteogenic protein in the TGF-beta family [J]. EMBO J, 1990, 9(7): 2085-2093.
|
23 |
Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions [J]. J Bone Joint Surg Am, 2001, 83-A Suppl 1(Pt 2): S151-S158.
|
24 |
White AP, Vaccaro AR, Hall JA, et al. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion [J]. Int Orthop, 2007, 31(6): 735-741.
|
25 |
Vaccaro AR, Whang PG, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study [J]. Spine J, 2008, 8(3): 457-465.
|
26 |
DiGiovanni CW, Lin SS, Baumhauer JF, et al. Recombinant human platelet-derived growth factor-BB and beta-tricalcium phosphate (rhPDGF-BB/β-TCP): an alternative to autogenous bone graft [J]. J Bone Joint Surg Am, 2013, 95(13): 1184-1192.
|
27 |
Yamaguchi JT, Weiner JA, Minardi S, et al. Characterizing the host response to rhPDGF-BB in a rat spinal arthrodesis model [J]. JOR Spine, 2021, 4(4): e1173.
|
28 |
Krishnan V, Lakshmi T. Bioglass: a novel biocompatible innovation [J]. J Adv Pharm Technol Res, 2013, 4(2): 78-83.
|
29 |
Bhatnagar RS, Qian JJ, Wedrychowska A, et al. Design of biomimetic habitats for tissue engineering with P-15, a synthetic peptide analogue of collagen [J]. Tissue Eng, 1999, 5(1): 53-65.
|
30 |
Sathe A, Lee SH, Kim SJ, et al. Comparative analysis of ABM/P-15, bone morphogenic protein and demineralized bone matrix after instrumented lumbar interbody fusion [J]. J Korean Neurosurg Soc, 2022, 65(6): 825-833.
|
31 |
Arnold PM, Sasso RC, Janssen ME, et al. i-Factor™ bone graft vs autograft in anterior cervical discectomy and fusion: 2-Year follow-up of the randomized Single-Blinded food and drug administration investigational device exemption study [J]. Neurosurgery, 2018, 83(3): 377-384.
|
32 |
国家食品药品监督管理总局. YY/T 1562—2017,组织工程医疗器械产品生物材料支架细胞活性试验指南. 2017.
|
33 |
孙嘉怿,张家振.新材料骨植入医疗器械审评方法研究及相关思考[J].生物骨科材料与临床研究, 2023, 20(5): 90-93.
|
34 |
中国食品药品检定研究院,组织工程类医疗产品分类界定指导原则[EB/OL].
URL
|
35 |
国家食品药品监督管理局,关于药械组合产品注册有关事宜的通告[EB/OL]. 2009.
URL
|